The 2026 National Institute on Aging report establishes that mild cognitive impairment and dementia are underdiagnosed. Mild cognitive impairment means early, measurable memory or thinking changes that do not yet block daily life. For spouses and partners, the report calls for routine risk-based screening across care settings. It leaves open which treatment or daily-care model works once that early signal appears.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why does dementia go undetected?
- What helped clinics find more cases?
- Why does timing matter for a spouse?
- What risks and gaps remain for partners?
Why does dementia go undetected?
Primary care often misses early change because guidelines do not consistently recommend screening. The National Institute on Aging states in its 2026 summit report that mild cognitive impairment and dementia remain underdiagnosed. The report urges routine risk-based screening instead of waiting for a crisis.
It also calls for technology-enhanced screeners and record-based algorithms adapted for education, language, and culture. That shift matters for partners who notice change first. A structured screen gives them a concrete result to act on.
What helped clinics find more cases?
A large Indianapolis trial tested a practical two-part approach. Clinics used the 10-question Quick Dementia Rating System plus an AI Passive Digital Marker. Clinics using both tools had 31% higher odds of new dementia diagnoses than usual care, according to JAMA Network Open in its trial report.
The trial enrolled 5,325 primary-care patients in nine federally qualified health centers. The marker uses routine electronic health-record data to flag high-risk patients for follow-up. The design aims for zero added clinician time during the visit.
Why does timing matter for a spouse?
Mrs. Krebs needed two years to obtain a mild cognitive impairment diagnosis in her early 60s. The delay postponed access to FDA-approved donanemab.
Her husband also postponed switching to Medicare during the uncertainty. They later updated wills, powers of attorney, and trust documents. Donanemab, sold as Kisunla, has FDA traditional approval only for early symptomatic Alzheimer's with confirmed brain amyloid, according to the Alzheimer's Association in its donanemab treatment page. That means: Late diagnosis can close that treatment window.
- diagnosis at mild cognitive impairment or mild dementia stage
- confirmed brain amyloid
- IV infusion every four weeks
What risks and gaps remain for partners?
Spouses face their own elevated risk after a partner's diagnosis. A Taiwan nationwide matched cohort of 955,105 married adults found about 70% higher dementia risk in spouses, reported by JAMA Network Open via PubMed in its cohort record. Risk was markedly higher for both women and men.
The hazard ratio was 1.74 for women and 1.69 for men during 1998–2022 follow-up. The Summit report also leaves daily care unresolved. It recommends no single treatment or care model, and caregiver programs remain largely tested in controlled settings rather than real-world care. Only about 11% of caregivers report formal training in daily-living support.
You Might Also Like
- Community-Academic Dementia Partnerships in the 2026 NIA Report: What the Report Establishes and Leaves Unanswered for Spouses and Partners
- Culturally Responsive Caregiver Support in the 2026 NIA Report: What the Report Establishes and Leaves Unanswered for Spouses and Partners
- The 2026 NIA Workshop on Comprehensive Dementia Care Models: Care-Planning Implications for Long-Distance Caregivers
